AlphAIAlphAI — Financial news for AI agents
tradingview.com$GKOS

Glaukos Shares November 2026 Investor Presentation, Citing 30% 2025 Growth

Glaukos (GKOS) presented its November 2026 investor deck, projecting 30% revenue growth in 2025. The company highlighted 14 pipeline programs, 12 commercial products, and FDA approvals for iDose TR and Epioxa. As of Q3 2026, Glaukos reported $340M in cash, no debt, and an 88% adjusted gross margin.

Original reporting
tradingview.com
Published Nov 6, 2026, 12:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Glaukos Shares November 2026 Investor Presentation, Citing 30% 2025 Growth — source image
Source · tradingview.com
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The repeat of existing guidance offers no new trading edge; investors have already incorporated the numbers.

02

Market read

Pure recap of already‑public earnings guidance; low trading relevance.

03

What to watch

None identified beyond the recapped figures.

Relevance 4/10Novelty 2/10Timing: none – information already known

Background

Glaukos Corp (GKOS) filed an 8‑K on Nov 6, 2026, summarizing its investor presentation that reiterates 2025 growth guidance and Q3 cash/margin metrics previously disclosed in the Oct 28 earnings release.

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

The article recaps Glaukos' November 2026 investor presentation, repeating guidance and cash figures already disclosed in the Oct. 28 earnings release.

Expected impact

little to no immediate price movement expected

Evidence & confidence

All numbers (30% growth guidance, $340 M cash, 88% margin) were public nine days earlier; the piece adds no fresh data.

Market effects

Sector

None; the ophthalmic device sector receives no new catalyst.

Regional

None; the recap is US‑focused and does not affect broader markets.

Global

Minimal

Counterpoint

What could challenge this read

No contrarian angle; the data is already priced.

Key entities

  • company
    Glaukos Corp

    US‑listed ophthalmic device maker (NASDAQ: GKOS).

Read at source← All news

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com